Disease Landscape and Forecast Insights

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Multiple myeloma remains an incurable hematological malignancy despite the availability of numerous treatment options. Resistance to therapy is the primary challenge associated with the disease’…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark,…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the American markets (Argentina, Canada, Chile, Colombia…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (China, India,…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IPF…

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts of key idiopathic pulmonary fibrosis (IPF) patient populations covering 171…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the Asia-Pacific region (Australia, Hong Kong, Indonesia…